Edition:
United Kingdom

Acceleron Pharma Inc (XLRN.OQ)

XLRN.OQ on NASDAQ Stock Exchange Global Market

45.88USD
5:39pm GMT
Change (% chg)

$-1.94 (-4.06%)
Prev Close
$47.82
Open
$47.58
Day's High
$47.58
Day's Low
$45.79
Volume
109,602
Avg. Vol
127,992
52-wk High
$59.54
52-wk Low
$32.62

Latest Key Developments (Source: Significant Developments)

Celgene Corp, Acceleron Pharma Announce Results Of Phase 3 Medalist Trial Evaluating Luspatercept In Patients With Myelodysplastic Syndromes
Sunday, 2 Dec 2018 

Dec 2 (Reuters) - Celgene Corp ::ORATION AND ACCELERON PHARMA ANNOUNCE RESULTS OF THE PHASE 3 MEDALIST TRIAL EVALUATING LUSPATERCEPT IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AT THE ASH 2018 PLENARY SESSION.REGULATORY SUBMISSIONS PLANNED IN UNITED STATES AND EUROPE IN FIRST HALF OF 2019.MEDALIST MET PRIMARY ENDPOINT OF RED BLOOD CELL TRANSFUSION INDEPENDENCE (RBC-TI) FOR 8 OR MORE WEEKS DURING FIRST 24 WEEKS OF STUDY.  Full Article

Acceleron Receives FDA Fast Track Designation For ACE-083 In Charcot-Marie-Tooth Disease
Wednesday, 28 Nov 2018 

Nov 28 (Reuters) - Acceleron Pharma Inc ::ACCELERON RECEIVES FDA FAST TRACK DESIGNATION FOR ACE-083 IN CHARCOT-MARIE-TOOTH DISEASE.ACCELERON PHARMA INC - PRELIMINARY RESULTS FROM PART 2 OF TRIALS ARE EXPECTED BY YEAR END 2019 FOR CMT AND IN SECOND HALF OF 2019 FOR FSHD.  Full Article

Acceleron Pharma Inc - QTRLY Loss Per Share $0.63
Thursday, 2 Aug 2018 

Acceleron Pharma Inc ::ACCELERON REPORTS SECOND QUARTER 2018 OPERATING AND FINANCIAL RESULTS.ACCELERON PHARMA - BELIEVES EXISTING CASH, CASH EQUIVALENTS AND INVESTMENTS WILL BE SUFFICIENT TO FUND PROJECTED OPERATING REQUIREMENTS INTO 2021.ACCELERON PHARMA INC - CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF JUNE 30, 2018 WERE $332.3 MILLION..ACCELERON PHARMA INC - QTRLY LOSS PER SHARE $0.63.ACCELERON PHARMA INC - COLLABORATION REVENUE FOR Q2 WAS $3.7 MILLION.  Full Article

Acceleron Announces Prelim Results From Phase 2 Charcot-Marie-Tooth Disease Trial
Monday, 23 Jul 2018 

July 23 (Reuters) - Acceleron Pharma Inc ::ACCELERON ANNOUNCES PRELIMINARY RESULTS FROM PART 1 OF THE ACE-083 PHASE 2 TRIAL IN PATIENTS WITH CHARCOT-MARIE-TOOTH DISEASE AT THE 2018 ANNUAL MEETING OF THE PERIPHERAL NERVE SOCIETY.ACCELERON ANNOUNCES PRELIMINARY RESULTS FROM PART 1 OF THE ACE-083 PHASE 2 TRIAL IN PATIENTS WITH CHARCOT-MARIE-TOOTH DISEASE AT THE 2018 ANNUAL MEETING OF THE PERIPHERAL NERVE SOCIETY.ACCELERON PHARMA INC - MEAN TOTAL MUSCLE VOLUME INCREASES OF MORE THAN 12% SEEN IN TIBIALIS ANTERIOR.ACCELERON PHARMA INC - COMPANY PLANS TO INITIATE PART 2 OF CMT PHASE 2 TRIAL IN Q3 OF 2018.ACCELERON PHARMA INC - PRELIMINARY RESULTS EXPECTED BY END OF 2019 FOR PART 2 CMT PHASE 2 TRIAL.  Full Article

Acceleron Receives FDA Orphan Drug Designation For Ace-083 In Facioscapulohumeral Muscular Dystrophy
Thursday, 12 Jul 2018 

July 12 (Reuters) - Acceleron Pharma Inc ::ACCELERON RECEIVES FDA ORPHAN DRUG DESIGNATION FOR ACE-083 IN FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY.ACCELERON RECEIVES FDA ORPHAN DRUG DESIGNATION FOR ACE-083 IN FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY.ACCELERON PHARMA INC - TO SHARE PART 2 RESULTS FOR ACE-083 IN FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY LATER NEXT YEAR.  Full Article

Celgene And Acceleron says Luspatercept Achieved main goals in study
Monday, 9 Jul 2018 

July 10 (Reuters) - Celgene Corp ::CELGENE AND ACCELERON ANNOUNCE LUSPATERCEPT ACHIEVED PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN PHASE III ‘BELIEVE’ STUDY IN ADULTS WITH TRANSFUSION-DEPENDENT BETA-THALASSEMIA.CELGENE CORP - RESULTS SHOWED A SIGNIFICANT REDUCTION IN TRANSFUSION BURDEN COMPARED TO PLACEBO.CELGENE CORP - REGULATORY SUBMISSIONS PLANNED IN UNITED STATES AND EUROPE IN FIRST HALF OF 2019.CELGENE CORP - SAFETY PROFILE GENERALLY CONSISTENT WITH PREVIOUSLY REPORTED DATA.CELGENE CORP - ADVERSE EVENTS OBSERVED IN STUDY WERE GENERALLY CONSISTENT WITH PREVIOUSLY REPORTED DATA.CELGENE CORP - DATA FROM BELIEVE AND MEDALIST WILL BE SUBMITTED TO A FUTURE MEDICAL MEETING IN 2018.  Full Article

Acceleron Receives FDA Fast Track Designation For Ace-083 In Facioscapulohumeral Muscular Dystrophy
Tuesday, 1 May 2018 

May 1 (Reuters) - Acceleron Pharma Inc ::ACCELERON RECEIVES FDA FAST TRACK DESIGNATION FOR ACE-083 IN FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD).  Full Article

Acceleron plans to initiate part 2 of ACE-083 FSHD phase 2 trial during Q2 of 2018
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Acceleron Pharma Inc ::ACCELERON PHARMA INC - PLANS TO INITIATE PART 2 OF ACE-083 FSHD PHASE 2 TRIAL DURING Q2 OF 2018.ACCELERON ANNOUNCES PRELIMINARY RESULTS FROM PART 1 OF THE ACE-083 PHASE 2 TRIAL IN PATIENTS WITH FACIOSCAPULOHUMERAL DYSTROPHY.  Full Article

Acceleron Pharma qtrly net loss per share $0.65
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Acceleron Pharma Inc :Acceleron Pharma reports third quarter 2017 operational and financial results.Acceleron Pharma Inc - ‍existing cash, cash equivalents and investments will be sufficient to fund projected operating requirements into 2021​.Acceleron Pharma Inc qtrly net loss per share applicable to common stockholders basic and diluted $0.65.Q3 earnings per share view $-0.64 -- Thomson Reuters I/B/E/S.  Full Article